Related Experiment Video
Updated: Feb 15, 2026
Highly Sensitive Measurement of Glomerular Permeability in Mice with Fluorescein Isothiocyanate-polysucrose 70
Published on: August 9, 2019
[Nephrology]
Sophie De Seigneux1, Belen Ponte1, Karine Hadaya1
1Service de néphrologie, Département des spécialités médicales, HUG, 1211 Genève 14.
Insights
New antidiabetic drugs effectively slow diabetic nephropathy progression. Prophylactic hydration offers no benefit for contrast nephropathy in moderate chronic kidney disease. Hemodiafiltration may be better tolerated in elderly patients, with similar myocardial stress compared to hemodialysis. Donor-specific antibodies are key in graft rejection.
Area of Science:
- Nephrology
- Endocrinology
- Immunology
Background:
- Diabetic nephropathy is a major complication of diabetes.
- Contrast-induced nephropathy is a concern in patients with chronic kidney disease.
- Graft rejection remains a challenge in organ transplantation.
Purpose of the Study:
- To review recent advancements in managing diabetic nephropathy.
- To evaluate the efficacy of prophylactic hydration in preventing contrast nephropathy.
- To compare hemodiafiltration and hemodialysis in elderly patients.
- To elucidate the role of donor-specific antibodies in graft rejection.
Main Methods:
- Review of current literature on antidiabetic drugs.
- Analysis of studies on prophylactic hydration and contrast nephropathy.
- Comparison of hemodiafiltration and hemodialysis outcomes in elderly patients.
- Characterization of de novo donor-specific antibodies in graft rejection.
Main Results:
- New antidiabetic drugs show effectiveness in slowing diabetic nephropathy.
- Prophylactic hydration does not prevent contrast nephropathy in moderate chronic kidney disease.
- Hemodiafiltration appears better tolerated than hemodialysis in elderly patients, with similar myocardial stress.
- The role of de novo donor-specific antibodies in graft rejection is increasingly understood.
Conclusions:
- Effective management strategies for diabetic nephropathy are emerging.
- Hydration is not beneficial for preventing contrast nephropathy in this patient group.
- Hemodiafiltration may offer advantages for elderly dialysis patients.
- Better understanding of donor-specific antibodies may lead to improved treatments for graft rejection.
Abstract:
New antidiabetic drugs which slow effectively the course of diabetic nephropathy are now available. There is no benefit of prophylactic hydratation to prevent contrast nephropathy in patients with moderate chronic kidney disease. In elderly hemodialysis patients, hemodiafiltration seems better tolerated than conventional hemodialysis, although there is a similar dialysis-induced myocardial stress with both methods. Role of de novo donor-specific antibodies is better characterized, which may subsequently lead to new treatments of graft rejection.
